Latest Insider Transactions at Olema Pharmaceuticals, Inc. (OLMA)
This section provides a real-time view of insider transactions for Olema Pharmaceuticals, Inc. (OLMA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Olema Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Olema Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 17
2024
|
G. Walmsley Graham Director |
SELL
Open market or private purchase
|
Indirect |
700,761
-33.22%
|
$4,204,566
$6.75 P/Share
|
|
Dec 17
2024
|
G. Walmsley Graham Director |
SELL
Open market or private sale
|
Indirect |
700,761
-100.0%
|
$4,204,566
$6.75 P/Share
|
|
Dec 16
2024
|
Naseem Zojwalla CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
14,000
+9.76%
|
$56,000
$4.87 P/Share
|
|
Dec 11
2024
|
Naseem Zojwalla CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
14,522
-5.6%
|
$130,698
$9.03 P/Share
|
|
Dec 11
2024
|
David C. Myles CH. DISCOV. & NON-CLIN DEV OFF |
SELL
Open market or private sale
|
Direct |
13,614
-1.11%
|
$122,526
$9.03 P/Share
|
|
Dec 11
2024
|
Cyrus Harmon |
SELL
Open market or private sale
|
Direct |
8,137
-0.53%
|
$73,233
$9.03 P/Share
|
|
Dec 11
2024
|
Sean Bohen PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
57,174
-9.61%
|
$514,566
$9.03 P/Share
|
|
Dec 11
2024
|
Shane William Charles Kovacs CH. OPERATING & FINANCIAL OFF. |
SELL
Open market or private sale
|
Direct |
18,356
-1.63%
|
$165,204
$9.03 P/Share
|
|
Dec 10
2024
|
Naseem Zojwalla CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
13,283
-9.27%
|
$119,547
$9.37 P/Share
|
|
Dec 10
2024
|
David C. Myles CH. DISCOV. & NON-CLIN DEV OFF |
SELL
Open market or private sale
|
Direct |
12,452
-1.99%
|
$112,068
$9.38 P/Share
|
|
Dec 10
2024
|
Cyrus Harmon |
SELL
Open market or private sale
|
Direct |
8,256
-1.06%
|
$74,304
$9.37 P/Share
|
|
Dec 10
2024
|
Sean Bohen PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
52,328
-14.9%
|
$470,952
$9.37 P/Share
|
|
Dec 10
2024
|
Shane William Charles Kovacs CH. OPERATING & FINANCIAL OFF. |
SELL
Open market or private sale
|
Direct |
16,803
-2.9%
|
$151,227
$9.37 P/Share
|
|
Dec 09
2024
|
Naseem Zojwalla CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
52,000
+26.62%
|
-
|
|
Dec 09
2024
|
David C. Myles CH. DISCOV. & NON-CLIN DEV OFF |
BUY
Grant, award, or other acquisition
|
Direct |
48,750
+7.24%
|
-
|
|
Dec 09
2024
|
Cyrus Harmon |
BUY
Grant, award, or other acquisition
|
Direct |
29,250
+3.61%
|
-
|
|
Dec 09
2024
|
Sean Bohen PRESIDENT AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
204,750
+36.83%
|
-
|
|
Dec 09
2024
|
Shane William Charles Kovacs CH. OPERATING & FINANCIAL OFF. |
BUY
Grant, award, or other acquisition
|
Direct |
68,250
+10.55%
|
-
|
|
Dec 04
2024
|
Bvf Partners L P Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,369,704
-35.73%
|
-
|
|
Nov 15
2024
|
Shane William Charles Kovacs CH. OPERATING & FINANCIAL OFF. |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+4.67%
|
$175,000
$7.02 P/Share
|
|
Aug 01
2024
|
Paradigm Biocapital Advisors LP > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
2,400,000
-34.36%
|
$33,600,000
$14.91 P/Share
|
|
Jul 30
2024
|
Cyrus Harmon |
SELL
Open market or private sale
|
Direct |
934
-0.12%
|
$14,010
$15.55 P/Share
|
|
Jul 29
2024
|
Cyrus Harmon |
SELL
Open market or private sale
|
Direct |
4,066
-0.54%
|
$60,990
$15.58 P/Share
|
|
Jul 11
2024
|
Cyrus Harmon |
SELL
Open market or private sale
|
Direct |
5,000
-0.66%
|
$60,000
$12.26 P/Share
|
|
Jun 28
2024
|
Cyrus Harmon |
SELL
Open market or private sale
|
Direct |
20,000
-2.56%
|
$200,000
$10.77 P/Share
|
|
Jun 04
2024
|
G. Walmsley Graham Director |
SELL
Open market or private sale
|
Indirect |
1,175,000
-45.06%
|
$16,450,000
$14.85 P/Share
|
|
Jun 04
2024
|
Cyrus Harmon |
SELL
Open market or private sale
|
Direct |
5,000
-0.64%
|
$60,000
$12.33 P/Share
|
|
Jun 03
2024
|
Cyrus Harmon |
SELL
Open market or private sale
|
Direct |
5,000
-0.63%
|
$50,000
$10.93 P/Share
|
|
May 31
2024
|
Cyrus Harmon |
SELL
Open market or private sale
|
Direct |
15,000
-1.86%
|
$135,000
$9.41 P/Share
|
|
May 24
2024
|
Naseem Zojwalla CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
9,460
+9.53%
|
$37,840
$4.87 P/Share
|
|
May 06
2024
|
Cyrus Harmon |
SELL
Open market or private sale
|
Direct |
5,000
-0.62%
|
$50,000
$10.92 P/Share
|
|
Apr 30
2024
|
Cyrus Harmon |
SELL
Open market or private sale
|
Direct |
15,000
-1.82%
|
$135,000
$9.51 P/Share
|
|
Mar 28
2024
|
Cyrus Harmon |
SELL
Open market or private sale
|
Direct |
20,000
-2.36%
|
$200,000
$10.97 P/Share
|
|
Mar 18
2024
|
Naseem Zojwalla CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
13,700
+14.56%
|
$54,800
$4.87 P/Share
|
|
Mar 05
2024
|
Andrew Rappaport |
BUY
Other acquisition or disposition
|
Indirect |
385,965
+50.0%
|
-
|
|
Mar 05
2024
|
Andrew Rappaport |
SELL
Other acquisition or disposition
|
Indirect |
481,014
-100.0%
|
-
|
|
Feb 29
2024
|
Cyrus Harmon |
SELL
Open market or private sale
|
Direct |
25,000
-1.43%
|
$300,000
$12.71 P/Share
|
|
Feb 01
2024
|
Cyrus Harmon |
SELL
Open market or private sale
|
Direct |
5,000
-0.57%
|
$75,000
$15.56 P/Share
|
|
Jan 31
2024
|
Cyrus Harmon |
SELL
Open market or private sale
|
Direct |
25,000
-2.77%
|
$300,000
$12.23 P/Share
|
|
Jan 25
2024
|
Naseem Zojwalla CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+23.08%
|
$140,000
$7.02 P/Share
|
|
Jan 12
2024
|
Shane William Charles Kovacs CH. OPERATING & FINANCIAL OFF. |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+9.35%
|
$350,000
$7.02 P/Share
|
|
Dec 29
2023
|
Cyrus Harmon |
SELL
Open market or private sale
|
Direct |
25,000
-1.35%
|
$325,000
$13.7 P/Share
|
|
Dec 12
2023
|
Shane William Charles Kovacs CH. OPERATING & FINANCIAL OFF. |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+2.25%
|
$70,000
$7.02 P/Share
|
|
Dec 11
2023
|
Naseem Zojwalla CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,900
+5.85%
|
$20,300
$7.02 P/Share
|
|
Dec 06
2023
|
Paradigm Biocapital Advisors LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
100,000
+1.49%
|
$1,100,000
$11.6 P/Share
|
|
Dec 06
2023
|
Naseem Zojwalla CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
13,100
+23.04%
|
$91,700
$7.02 P/Share
|
|
Dec 05
2023
|
G. Walmsley Graham Director |
BUY
Open market or private purchase
|
Indirect |
131,870
+2.44%
|
$1,846,180
$14.26 P/Share
|
|
Nov 30
2023
|
Cyrus Harmon |
SELL
Open market or private sale
|
Direct |
25,000
-2.63%
|
$300,000
$12.57 P/Share
|
|
Nov 22
2023
|
Shane William Charles Kovacs CH. OPERATING & FINANCIAL OFF. |
SELL
Open market or private sale
|
Direct |
9,145
-2.11%
|
$118,885
$13.89 P/Share
|
|
Nov 22
2023
|
Sean Bohen PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
27,932
-16.16%
|
$363,116
$13.9 P/Share
|